Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Rating of “Hold” from Analysts

Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) have earned a consensus rating of “Hold” from the fifteen brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $55.1364.

Several research analysts have recently commented on TERN shares. Citizens Jmp downgraded Terns Pharmaceuticals from a “market outperform” rating to a “hold” rating in a research note on Thursday, March 26th. Wall Street Zen upgraded Terns Pharmaceuticals to a “sell” rating in a research note on Saturday. BMO Capital Markets downgraded Terns Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 26th. Mizuho set a $53.00 price target on Terns Pharmaceuticals in a report on Friday, March 27th. Finally, HC Wainwright reissued a “neutral” rating and set a $53.00 price target (down from $60.00) on shares of Terns Pharmaceuticals in a report on Wednesday, March 25th.

Terns Pharmaceuticals Stock Performance

Shares of NASDAQ TERN opened at $52.95 on Tuesday. Terns Pharmaceuticals has a 12 month low of $2.65 and a 12 month high of $53.19. The stock has a 50 day moving average of $49.68 and a 200-day moving average of $37.90. The company has a market capitalization of $6.12 billion, a P/E ratio of -51.41 and a beta of -0.37.

Terns Pharmaceuticals (NASDAQ:TERN) last issued its earnings results on Monday, March 30th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.06. Analysts predict that Terns Pharmaceuticals will post -1.22 EPS for the current fiscal year.

Insider Activity at Terns Pharmaceuticals

In related news, CEO Amy L. Burroughs sold 14,583 shares of Terns Pharmaceuticals stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $46.71, for a total transaction of $681,171.93. Following the completion of the sale, the chief executive officer directly owned 288,976 shares of the company’s stock, valued at approximately $13,498,068.96. This trade represents a 4.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Emil Kuriakose sold 942 shares of Terns Pharmaceuticals stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $52.75, for a total value of $49,690.50. Following the sale, the insider directly owned 105,673 shares of the company’s stock, valued at approximately $5,574,250.75. The trade was a 0.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 30,108 shares of company stock valued at $1,302,370. 1.50% of the stock is currently owned by insiders.

Institutional Trading of Terns Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Fifth Third Bancorp acquired a new stake in Terns Pharmaceuticals during the 1st quarter worth approximately $32,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Terns Pharmaceuticals in the 4th quarter valued at $25,000. GAMMA Investing LLC raised its holdings in Terns Pharmaceuticals by 762.4% in the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock valued at $35,000 after acquiring an additional 770 shares in the last quarter. iA Global Asset Management Inc. acquired a new position in Terns Pharmaceuticals in the 4th quarter valued at $43,000. Finally, KBC Group NV acquired a new position in Terns Pharmaceuticals in the 1st quarter valued at $89,000. 98.26% of the stock is owned by institutional investors and hedge funds.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.